Pharma Focus Asia
Klöckner Pentaplast - Pentapharm® alfoil® films

PhaseBio to Announce PB2452, a Novel Reversal Agent for Antiplatelet Drug Ticagrelor

PhaseBio Pharmaceuticals is planning to announce PB2452, a novel reversal agent for the Antiplatelet drug Ticagrelor.

PB2452 is a novel, recombinant, human monoclonal antibody antigen-binding fragment, or Fab fragment, designed to reverse the Antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.

PB2452 achieved immediate and sustained reversal of ticagrelor’s Antiplatelet effects in Phase I trial results.

It highlights the critical unmet need for a therapy to reverse the antiplatelet activity of Ticagrelor, which is widely prescribed to patients with acute coronary syndrome or a history of heart attack.

The results from the Phase I clinical trial of PB2452 exhibited immediate and sustained reversal of the antiplatelet activity of ticagrelor, which could mitigate bleeding concerns associated with use of ticagrelor.

The dose-escalation trial was designed to evaluate the safety and tolerability and determine proof of concept for PB2452 as a ticagrelor reversal agent in healthy subjects pre-dosed with ticagrelor.

PB2452 achieved rapid, complete and sustained reversal of ticagrelor’s antiplatelet activity with potential customizable duration of reversal based on the dosing regimen, in the trial.

In addition, there were no PB2452-related adverse events or serious adverse events reported.

The availability of a reversal agent such as PB2452 could uniquely position ticagrelor as the only oral Antiplatelet drug with a reversal agent and expand its use by mitigating concerns regarding the bleeding risk associated with Antiplatelet drugs.

magazine-slider-imageBIOVIA from Molecule to MedicineMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024Advance DoE WorkshopCPHI Korea 2024CHEMICAL INDONESIA 2024INALAB 2024 Thermo Scientific - DynaDrive and DynaSpinRehab Expo 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024